Diagnostics and therapy of systemic mastocytosis;Zur diagnose und therapie der systemischen mastozytose

Medizinische Welt

Volumn 58, Issue 12, 2007, Pages 621-631

  Alfter, K ^a   Von Kugelgen I ^b   Kolck, U W ^a   Noe, G ^a   Frieling, Th ^c   Hertfelder, H J ^b   Oldenburg, J ^b   Homann, J ^a   Molderings, Gerhard J ^b  

^a Evangelische Kliniken Bonn gGmbH   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Klinikum Krefeld   (Germany)

Author keywords

Diagnosis; Irritable bowel syndrome; Systemic mastocytosis

Indexed keywords

ANTIHISTAMINIC AGENT;

BIOPSY TECHNIQUE; CELL MEMBRANE; CELL PROLIFERATION; HUMAN; LABORATORY TEST; MAST CELL; QUESTIONNAIRE; REVIEW; SYSTEMIC MASTOCYTOSIS;

EID: 37149011346     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Akin C. Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 2005; 114: 61-9.
2. Akin C et al. A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib. Blood 2004; 103: 3222-3225.
3. AWMF-Leitlinien-Register Nr.061/018. Allergo J 2004; 13: 440-442.
4. Barbara G et al. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006; 18: 6-17.
5. Barrett KE. Mechanisms for amplified mediator release from colonic mast cells: Implications for intestinal inflammatory diseases. World J Gastroenterol 2004; 10: 617-619.
6. Berman E et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. New Engl J Med 2006; 354: 2006-2012.
7. Brockow K et al. IL- 6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005; 115: 216-223.
8. Butterfield JH, Li CY. Bone marrow biopsies for the diagnosis of systemic mastocytosis - Is one biopsy sufficient? Am J Clin Pathol 2004; 121: 264-267.
9. Casassus P et al. Treatment of adult systemic mastocytosis with interferon-α: results of a multicentre phase II trial on 20 patients. Br J Haematology 2002; 119: 1090-1097.
10. Caughey GH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol 2006; 117: 1411-1414.
11. Droogendijk HJ et al. Imatinib mesylate in the treatment of systemic mastocytosis - a phase II trial. Cancer 2006; 107: 345-351.
12. Drossman DA. Appendix C. Rome III diagnostic questionnaire for the adult functional GI disorders (including alarm questions) and scoring algorithm. In: Drossman DA (ed) Rome III. The Functional Gastrointestinal Disorders. Third Edition. Rome III, c/o Degnon Associates, USA, ISBN 0-9656837-6-1.
13. Escribano L et al. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy - Drug Targets 2006; 5: 61-77.
14. Frieling T et al. Neuroimmune communication in the submucous plexus of guinea pig colon after infection with Trichinella spiralis. Gastroenterology 1994; 107: 1602-1609.
15. Galli SJ et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005; 23: 749-786.
16. Garcia-Montero AC et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
17. He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 2004; 10: 309-318.
18. Kerkela R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916.
19. Kluin-Nelemans H, Oldhoff JM, van Doormaal JJ. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270-4276.
20. Kulka M, Metcalfe DD. High-resolution tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro: correlation with apoptosis and KIT expression. Blood 2005; 105: 592-599.
21. Matsuzawa S et al. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 2003; 170: 3461-3467.
22. Matter SE, Bhatia PS, Miner PB. Evaluation of antral mast cells in nonulcer dyspepsia. Dig Dis Sci 1990; 35: 1358-1363.
23. Molderings GJ et al. Systemische Mastozytose als Grund für chronische gastrointestinale Beschwerden. Dtsch Arztebl 2005; 102: A1744-A1749.
24. Molderings GJ et al. Die systemische Mastzellerkrankung mit gastrointestinal betonter Symptomatik - eine Checkliste als Diagnoseinstrument. Dtsch Med Wochenschr 2006; 131: 2095-2100.
25. Molderings GJ et al. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 2007; 42: 1045-1053.
26. Nakahata T et al. Extensive proliferation of mature connective-tissue type mast cells in vitro. Nature 1986; 324: 65-67.
27. Nakamura R et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006; 37: 353-358.
28. Pardanani A et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535-536.
29. Park JH et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21: 71-78.
30. Qi JC et al. An antibody raised against in vitro-derived human mast cells identifies mature mast cells and population of cells that are FcεRI+, Tryptase-, and Chymase- in a variety of human tissues. J Histochem Cytochem 2003; 51: 643-653.
31. Quintas-Cardama A et al. Novel approach in the treatment of systemic mastocytosis. Cancer 2006; 107: 1429-1439.
32. Rohr SM, Rich MW, Silver KH. Shortness of breath, syncope, and cardiac arrest caused by systemic mastocytosis. Ann Emerg Med 2005; 45: 592-594.
33. Rueff F et al. Mastozytose - klinisches Bild und Diagnostik. Dtsch Med Wochenschr 2006; 131: 1616-1621.
34. Santos J et al. Pathogenesis of irritable bowel syndrome: The mast cell connection. Scand J Gastroenterol 2005; 40: 129-140.
35. Schemann M et al. Human mast cell mediator cocktail excites neurons in human and guinea-pig enteric nervous system. Neurogastroenterol Motil 2005; 17: 281-289.
36. Schwartz LB, Irani AMA. Serum typtase and the laboratory diagnosis of systemic mastocytosis. Hematology/Oncology Clin North Am 2000; 14: 641-657.
37. Siegert SI et al. Are gastrointestinal mucosal mast cells increased in patients with systemic mastocytosis? Am J Clin Pathol 2004; 122: 560-565.
38. Simon J et al. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 2004; 52: 294-299.
39. Sonneck K et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal Mast Cell Activation Syndrome. Int Arch Allergy Immunol 2007; 142: 158-164.
40. Sotlar K et al. One-step detection of c- kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162: 737-746.
41. Soto D et al. Genetic dificiency of human mast cell alpha- tryptase. Clin Exp Allergy 2002; 32: 1000-1006.
42. Stefanini GF et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995; 30: 535-541.
43. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci 2006; 1088: 78-99.
44. Valent P et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymph 2005; 46: 35-48.
45. Vlieg-Boerstra BJ et al. Mastocytosis and adverse reactions to biogenic amines and histamine- releasing foods: what is the evidence? Neth J Med 2005; 63: 244-249.